TABLE 1.

Characteristics of CMV assays

AssayManufacturerAntigenTest type and procedureaUnitInterpretation of results
Architect CMV IgGAbbottViral lysateCMIA, two steps, indirect anti-IgG detectionAU/mlNonreactive, <6.0; reactive, ≥6.0
AxSYM CMV IgGAbbottViral lysateMEIA, two steps, indirect anti-IgG detectionAU/mlNegative, <5; positive, ≥15
Enzygnost CMV IgGSiemensPurified antigenEIA, two steps, indirect anti-IgG detectionAbsorbance valueNegative <0.100; positive, >0.200; equivocal, 0.100-0.200
Vidas CMV IgGBioMérieuxViral lysateELFA, two steps, indirect anti-IgG detectionAU/mlNegative, <4; positive, >6; equivocal, ≥4-≤6
Architect CMV IgMAbbottViral lysate and recombinant antigenCMIA, two steps, indirect anti-IgM detectionIndexNonreactive, <0.85; reactive, ≥1.00; equivocal, 0.85-0.99
AxSYM CMV IgMAbbottRecombinant antigenMEIA, two steps, indirect anti-IgM detectionIndexNegative, <0.400; positive, ≥0.500; equivocal, 0.400-0.499
Enzygnost CMV IgMSiemensPurified antigenEIA, two steps, indirect anti-IgM detectionAbsorbance valueNegative, <0.100; positive, >0.200; equivocal, 0.100-0.200
Vidas CMV IgMBioMérieuxViral lysateELFA, two steps, indirect anti-IgM detectionIndexNegative, <0.70; positive, ≥0.90; equivocal, 0.70-<0.89
Architect CMV IgG avidityAbbottViral lysateCMIA, two assays with and without liquid CMV antigen to neutralize high-avidity CMV antibodies% AvidityLow avidity, <50.0%; high avidity, >60.0%; equivocal, 50.0-59.9%
Vidas CMV IgG avidityBioMérieuxViral lysateELFA, two assays with and without 6 M urea to dissociate low-avidity antibodiesAvidity indexLow avidity, <0.2; high avidity, >0.8; equivocal, 0.2-<0.8
  • a CMIA, chemiluminescent microparticle immunoassay; MEIA, microparticle enzyme immunoassay; EIA, enzyme immunoassay; ELFA, enzyme-linked fluorescent assay.